|Dr. Matthew C. Coffey M.B.A., Ph.D.||President, CEO & Director||1.05M||N/A||N/A|
|Mr. Kirk J. Look C.A., CA||Chief Financial Officer||740.85k||N/A||N/A|
|Mr. Andrew R. de Guttadauro||Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc||634.74k||N/A||1967|
|Dr. Thomas C. Heineman M.D., Ph.D.||Chief Medical Officer||872.68k||N/A||N/A|
|Ms. Allison Hagerman P.Eng., P.M.P.||Vice President of Product Development||582.15k||N/A||N/A|
|Jon Patton||Director of Investor Relations & Communication||N/A||N/A||N/A|
|Mr. John Mark Lievonen F.C.A., FCA, LLD||Consultant||25.98k||N/A||N/A|
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.’s ISS Governance QualityScore as of December 1, 2023 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 2; Compensation: 8.